Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

ZNTL Zentalis Pharmaceuticals

Watchlist
22.970
-0.200-0.86%
Close  01/26 16:00 ET
High
23.720
Open
23.460
Turnover
5.44M
Low
22.430
Pre Close
23.170
Volume
238.45K
Market Cap
1.31B
P/E(TTM)
Loss
52wk High
59.650
Shares
57.07M
P/E(Static)
Loss
52wk Low
17.330
Float Cap
913.52M
Bid/Ask %
33.33%
Historical High
87.190
Shs Float
39.77M
Volume Ratio
0.57
Historical Low
17.330
Dividend TTM
--
Div Yield TTM
--
P/B
3.06
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.60%
Amplitude
5.57%
Avg Price
22.800
Lot Size
1
Float Cap
913.52M
Bid/Ask %
33.33%
Historical High
87.190
Shs Float
39.77M
Volume Ratio
0.57
Historical Low
17.330
Dividend TTM
--
P/B
3.06
Dividend LFY
--
Turnover Ratio
0.60%
Amplitude
5.57%
Avg Price
22.800
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.
CEO: Dr. Kimberly Blackwell, M.D.
Market: NASDAQ
Listing Date: 04/03/2020
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist